Boehringer Ingelheim and Evotec expand collaboration

Boehringer Ingelheim and Evotec are to double the size of their existing drug discovery collaboration.

The two companies first came together in September 2004 and their initial agreement on developing treatments acting on G-protein coupled receptors (GPCRs) has also been extended until the end of 2008

Evotec and Boehringer will now aim to jointly identify and develop pre-clinical development candidates suitable for future selection as drug candidates for clinical testing in different classes, including ion channels and enzymes.

Professor Mikael Dolsten, Boehringer Ingelheim head of pharma R&D, said: “We are very pleased with the progress we have achieved in our collaboration with Evotec to date.

“We appreciate the drug discovery performance with the first milestone achieved as well as the positive spirit in the team. This has led us to extend and expand our relationship further.”

Under the agreement Boehringer will take the ownership and global responsibility for all clinical development activities, manufacture and commercialisation of the compounds identified in the collaboration.

Evotec, which has sites in Hamburg, Oxford and Glasgow, will receive ongoing research payments from Boehringer along with pre-clinical and clinical milestones as well as royalties on drugs discovered in the collaboration.

© Adfero Ltd